Suppr超能文献

磷酸化组蛋白H3作为评估浸润性乳腺癌增殖标志物的价值:与Ki67的比较研究

The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67.

作者信息

Kim Ji-Ye, Jeong Hyang Sook, Chung Taek, Kim Moonsik, Lee Ji Hee, Jung Woo Hee, Koo Ja Seung

机构信息

Department of Pathology and Translational Genomics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.

Department of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.

出版信息

Oncotarget. 2017 May 10;8(39):65064-65076. doi: 10.18632/oncotarget.17775. eCollection 2017 Sep 12.

Abstract

BACKGROUND

Established measurements of proliferation in breast cancer are Ki67 and mitotic-activity-index (MAI), with problems in reproducibility and prognostic accuracy. Phosphohistone H3 (PHH3), a relatively novel IHC marker is specific for mitosis with good reproducibility. We hypothesized that PHH3 would be more reproducible and better represent proliferation than Ki67.

RESULTS

PHH3 identified easily-missed mitosis by MAI, as demonstrated by upgrading M grade at diagnosis ( 29/218, evenly distributed). PHH3 accurately found hot-spots, supported by mitotic count agreement between low-power and 10HPFs (R = 0.999; = 0.001). PHH3 was more reproducible than Ki67, measured by five-rater inter-class correlation coefficient (0.904 > 0.712; 0.008). Finally, despite a relatively short follow-up (median 46 months; 7 recurrences) PHH3 was the only variable correlated with disease-free survival ( 0.043), while all other conventional clinicopathologic variables, including Ki67 ( 0.356), did not.

MATERIALS AND METHODS

We compared Ki67 and PHH3 for 218 breast cancer surgical cases diagnosed from 2012 to 2013 at Severance hospital. The most representative invasive breast cancer surgical slides were immunohistochemically stained for Ki67 and PHH3.

CONCLUSIONS

Poor reproducibility and inadequate representation of proliferation of Ki67 and MAI may be improved by PHH3, allowing better accuracy in breast cancer diagnostics.

摘要

背景

乳腺癌中已确立的增殖测量指标是Ki67和有丝分裂活性指数(MAI),但存在可重复性和预后准确性方面的问题。磷酸化组蛋白H3(PHH3)是一种相对较新的免疫组化标志物,对有丝分裂具有特异性,且具有良好的可重复性。我们假设PHH3比Ki67具有更高的可重复性,并且能更好地代表增殖情况。

结果

PHH3能够识别MAI容易遗漏的有丝分裂,这在诊断时M分级的提升中得到了证明(29/218,分布均匀)。PHH3准确地找到了热点区域,低倍视野和10个高倍视野之间的有丝分裂计数一致性支持了这一点(R = 0.999;P = 0.001)。通过五评估者组内相关系数测量,PHH3比Ki67具有更高的可重复性(0.904 > 0.712;P = 0.008)。最后,尽管随访时间相对较短(中位时间46个月;7例复发),但PHH3是唯一与无病生存期相关的变量(P = 0.043),而包括Ki67在内的所有其他传统临床病理变量均无相关性(P = 0.356)。

材料与方法

我们对2012年至2013年在Severance医院诊断的218例乳腺癌手术病例的Ki67和PHH3进行了比较。选取最具代表性的浸润性乳腺癌手术切片进行Ki67和PHH3的免疫组化染色。

结论

PHH3可能会改善Ki67和MAI在增殖方面可重复性差和代表性不足的问题,从而提高乳腺癌诊断的准确性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验